Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus trastuzumab in HER2-positive BRCA-mutated or HRD advanced breast cancer
2018-001213-32Phase 2Active
- Sponsor
- MEDSIR
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and trastuzumab in breast cancer, sponsored by MEDSIR. Primary endpoints: Overall response rate and Progression-free survival. Started Nov 2018; status: active.
02
Drugs
olaparibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-001213-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001213-32.